Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650846 | 0.99 | TP53 (0.34) | TP53MAPTNPC1S1PR4LMNA | |
| SCHEMBL5106321 | 0.90 | TP53 (0.34) | TP53MAPTNPC1S1PR4LMNA | |
| SCHEMBL5105876 | 0.82 | TP53 (0.34) | TP53KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5498704 | 0.72 | TP53 (0.36) | TP53MAPTHTTTSHR | |
| SCHEMBL5112642 | 0.72 | ALDH1A1 (0.43) | TP53S1PR4HPGDCYP2C9CYP2C19 | |
| SCHEMBL5139368 | 0.71 | TP53 (0.33) | TP53KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5487155 | 0.71 | TP53 (0.38) | TP53TSHR | |
| SCHEMBL5113296 | 0.69 | TP53 (0.36) | TP53LMNAKMT2ACYP1A2CYP2C9 | |
| SCHEMBL5492086 | 0.65 | TP53 (0.36) | TP53HTTTSHR | |
| SCHEMBL5099902 | 0.64 | CRHR1 (0.55) | TP53DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20040235871-A1 | Crf receptor antagonists | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235871-A1 | Crf receptor antagonists | CRHR1, CRHR2, CRH | TP53 4688/4885MAPT 4815/4885NPC1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.